BioSante Pharmaceuticals to Present at Two International Health Care Conferences.LINCOLNSHIRE, Ill. -- BioSante Pharmaceuticals, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BPAX) today announced that Stephen M. Simes, its president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , will present a corporate update and overview at two upcoming international healthcare conferences. Mr. Simes will discuss the LibiGel([R]) (testosterone gel) clinical development plan and new primary research data indicating the potential size of the U.S. market for BioSante's LibiGel in the treatment of female sexual dysfunction. Both conferences will feature pharmaceutical and biotech companies presenting to institutional investors, portfolio managers and analysts from around the world interested in these sectors. The first conference is the Rodman & Renshaw Annual Global Healthcare Conference. Mr. Simes will be presenting on Monday, May 19, 2008 at 8:30 am EDT EDT abbr. Eastern Daylight Time EDT Eastern Daylight Time EDT n abbr (US) (= Eastern Daylight Time) → hora de verano de Nueva York EDT . The second conference is the BIOMED BIOMED Biomedical BIOMED Biological Medicine ISRAEL 2008 Healthcare Conference. Mr. Simes will be presenting on Wednesday, May 28, 2008 at 9:55 am EDT. A live audio webcast of BioSante's presentation at the Rodman & Renshaw Conference may be accessed at http://www.biosantepharma.com/Webcasts.php and a replay will be available at the same link for 60 days. About BioSante Pharmaceuticals, Inc. BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante's lead products include LibiGel([R]) (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD FSD Female Sexual Dysfunction FSD File System Driver FSD Family Support Division FSD Fire Services Department (Hong Kong) FSD Full Scale Development FSD Full Scale Deflection FSD Federal Systems Division ), and Elestrin[TM] (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor vasomotor /vaso·mo·tor/ (-mo´tor) 1. affecting the caliber of blood vessels. 2. a vasomotor agent or nerve. va·so·mo·tor adj. symptoms associated with menopause, currently marketed in the U.S. Also in development are Bio-T-Gel[TM], a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate technology (CaP) for novel vaccines, drug delivery and aesthetic medicine (BioLook[TM]). Additional information is available online at: www.biosantepharma.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion